Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Author(s): Chewki Ziani-Cherif, Bachir Mostefa-Kara, Fatima Z. Brixi-Gormat

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 33 , 2006

Become EABM
Become Reviewer
Call for Editor


Alzheimer disease (AD) is characterized by excessive deposition of amyloid β-peptides (Aβ peptides) in the form of senile plaques as well as neurofibrillary tangles (NFTs) in the brain. In the amyloidogenic pathway, the amyloid-β precursor protein (APP) is cleaved by β-secretase first, followed by γ-secretase cleavage producing therefore Aβ. This review summarizes the recent findings in the AD field and focuses on the different γ-secretase inhibitors that have been developed as a therapeutic approach toward AD.

Keywords: Alzheimer disease, amyloid βprecursor protein, amyloid β, γ-secretase, presenilins, γ-secretase inhibitors, nonsteroidal anti-inflammatory drugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [4313 - 4335]
Pages: 23
DOI: 10.2174/138161206778792994
Price: $65

Article Metrics

PDF: 3